口服异维A酸治疗中重度痤疮临床观察

我科自2003年起,采用异维A酸胶丸口服治疗中、重度痤疮患者,取得明显效果,且不良反应少,现将结果报告如下。1病例和方法1.1病例选择1.1.1入选标准入选患者具有典型的中、重度痤疮[1]的临床表现,病程2个月～3年,入选前多采用过其他药物治疗,效果不理想。年龄18～40岁,性别不限,愿意配合试验者。对育龄期妇女嘱其在服药期间及服药前1个月至停药后3个月严格避孕。1.1.2排除标准妊娠期和哺乳期妇女;患心、肝、肾功能不全者或系统性疾病者;血脂异常者;不能合作者。1.1.3剔除标准不遵医嘱用药者;未完成疗程或资料不全者;对异维A酸过敏或不能耐受…     

口服异维A酸治疗痤疮的研究

口服异维A酸是目前临床上最为有效的抗痤疮药物,可同时作用于痤疮发病的4个主要环节。异维A酸在皮脂腺细胞内独特的分子作用机制使其具有强大的抑制皮脂腺分泌活性,近来其对痤疮免疫和炎症反应的拮抗作用也越来越受到重视。口服异维A酸主要用于治疗结节囊肿型重度痤疮以及其他治疗效果不好的中、重度寻常痤疮,使用剂量应根据患者的体重、疗效、依从性及不良反应进行综合判定。小剂量[0.25~0.5 mg/(kg·d)]治疗可以显著降低药物的不良反应及增加患者依从性;累积剂量达60~120 mg/kg可以明显降低痤疮复发率。异维A酸不良反应大多以皮肤黏膜为主要表现,严重不良反应罕见,致畸是其最严重的不良反应。口服异维A酸能快速改善痤疮皮损,有效预防痤疮瘢痕形成,改善患者生活质量。     

异维A酸与痤疮

痤疮是一种毛囊皮脂腺的慢性炎性皮肤病,治疗方法较多,但存在起效慢、疗效不明确、易复发等问题。异维A酸是目前治疗痤疮最有效的药物,本文综述异维A酸治疗痤疮的机理、适合人群、临床疗效、安全性等。     

国产异维A酸胶囊治疗重症痤疮的疗效分析

目的观察国产异维A酸（泰尔丝）治疗重症痤疮的疗效与安全性。方法治疗组泰尔丝胶囊口服10mg／次,2次／d,饭后疗程3月;对照组必麦森凝胶和0．025％迪维霜乳膏外用早晚各一次,疗程3月。结果泰尔丝胶囊治疗重症痤疮的疗效自第2周起即可见效,至4～8周效果更明显,出现6例临床痊愈患者,不良反应少。至疗程结束有20例临床痊愈患者,显效12例,有效8例。总有效率达91％。而对照组2周时疗效不明显,局部皮肤不良反应明显。至4～8周仅有2例痊愈患者。至疗程结束有8例临床痊愈患者,显效14例,有效9例。总有效率72％。结论只要严格掌握其适应症和禁忌症,泰尔丝胶囊治疗重症痤疮的疗效是明显且安全的。     

异维A酸治疗中度寻常痤疮临床疗效观察

目的:评价异维A酸治疗中度痤疮的疗效和安全性。方法:采用随机、阳性药物平行对照的临床试验。试验组患者每日服用异维A酸(泰尔丝);对照组患者每日服用维胺酯,两组患者均治疗6周。治疗2、4、6周,对两组痤疮患者的粉刺、丘疹、脓疱、结节囊肿、皮脂溢出等评分比较。结果:试验组皮损的总评分差值从(0.2166±0.1291)分增至(6.2469±1.1826)分,对照组则从(0.1290±0.3191)分增至(5.6297±1.4489)分,两组间痤疮评分差值比较,差异有显著性。治疗结束时,试验组痊愈率和有效率分别为58.18%和100.00%,对照组分别为22.41%和82.75%,二组间疗效比较差异有显著性。试验组有23例患者出现局部不良反应,对照组有31例患者出现局部不良反应。结论:异维A酸治疗中度寻常痤疮疗效好于维胺酯。     

异维A酸胶丸治疗痤疮的疗效观察

笔者从2002年起采用异维A酸(商品名：泰尔丝)治疗难治性痤疮42例,取得了较好的临床效果,现报告如下。     

异维A酸在痤疮治疗中的应用

痤疮是一种影响大多数青少年的慢性炎症性疾病,主要累及面部和躯干,可能遗留各种类型的瘢痕,严重影响患者的生活质量.早期、有效和安全的治疗是解决疾病的关键.口服异维A酸是治愈或长期缓解中重度痤疮的独特治疗方法,它能抑制皮脂腺的活动,并具有抗炎和免疫调节功能,能及时有效的控制症状,可防止产生更多的瘢痕和心理社会影响.我们对异...     

异维A酸联合克林霉素治疗痤疮疗效观察

目的 :观察异维A酸联合克林霉素治疗痤疮的疗效。方法 :治疗组口服异维A酸胶丸每日2 0mg,分 2次口服 ,同时口服克林霉素胶囊每日 3 0 0mg,分 2次口服。 4周后异维A酸改为每日 1 0mg,1次顿服 ;克林霉素改为每日 1 5 0mg,1次顿服。对照组口服维生素B6片 ,每日 60mg,分 3次口服 ,同时口服四环素片每日 1g,分 2次口服。4周后四环素片改为每日 5 0 0mg,1次顿服。两组患者均外用氯霉素洗剂 ,每日 2次 ,共用 8周。结果 :停药时治疗组总有效率 81 7% ,对照组总有效率 2 8 3 %。两组比较有显著性差异 ( χ2 =3 4 48,P <0 0 0 1 )。结论 :异维A酸联合克林霉素治疗痤疮副作用小 ,疗效满意     

异维A酸治疗寻常痤疮66例

2005年6月至2007月4月，我科采用了异维A酸胶丸（商品名：泰尔丝，上海信谊延安药业有限公司生产）治疗寻常痤疮66例，取得了满意的疗效，现报告如下。1资料与方法1．1临床资料入选患者均为门诊病例，符合临床诊断标准。按Pillsbury分类法选择Ⅲ度、Ⅳ度患者。Ⅲ度患者32例，男18例，女14例，平均年龄22岁（18～30岁），病程3个月～2年；Ⅳ度患者34例，男21例，女13例，     

异维A酸隔日疗法和每日疗法治疗痤疮疗效比较

目的:观察异维A酸(泰尔丝)隔日疗法和每日疗法治疗痤疮的疗效,以及在保证疗效的前提下唾液腺分泌减少的发生率.方法:将受试者分为两组,即异维A酸隔日疗法B组(试验组)和每日疗法组(对照组).试验组中体重≥50kg者,隔日口服异维A酸10 mg,每日3次;体重＜50 kg者,隔日口服异维A酸10 mg,每日2次.对照组中体重≥50 kg者,每日口服异维A酸3次,每次10mg;体重＜50 kg者,每日口服异维A酸2次,每次10mg,两组患者疗程均为6周.结果:经过6周的治疗,试验组患者有效率为77.17%,对照组患者有效率为85.00%.第2、4、6周末时试验组和对照组患者唾液腺分泌减少的发生率分别为26%、31.25%、32.18%和28.87%、34.12%、48.68%.结论:异维A酸隔日疗法治疗痤疮的疗效与每日疗法相当,唾液腺分泌减少的发生率更低.     

Interest of the association retinaldehyde/glycolic acid in adult acne

Background  Topical retinoids have been successfully used in the treatment of acne vulgaris but may induce irritation when used twice daily. The association of retinaldehyde (RAL) with glycolic acid (GA) have complementary activities, which could be of interest for adult women with acne because of a better tolerance/efficacy ratio. The aim of this study was to evaluate the tolerance and the efficiency of RAL (0.1%)/GA (6%) in adult women with acne when used alone or in combination with their usual acne products except retinoids.
Methods  Three hundred ninety-seven women with acne (aged between 30 and 40 years old) were included in this open multicentric study. They had to apply cream containing RAL/GA for 90 days without stopping their previous acne treatment (except topical retinoids). The tolerance was the main criteria and the second one is the efficacy, which was assessed by counting inflammatory and retentional lesions after 30 and 90 days of treatment.
Results  Used alone or in association with other anti-acne treatments, RAL/GA was considered to be highly tolerated. A significant decrease in both inflammatory and retentional lesions between day 0 and day 90 indicates that RAL/GA can be used as monotherapy for mild acne or could potentate the efficiency of other anti-acne products used at the same time by patients suffering from moderate acne. Complaints about side-effects were rare. The subjective evaluation of the preparation's efficacy by investigators and patients was strongly favourable.
Conclusion  These data show that a combination of RAL 0.1% and GA 6% may be used in association with other topical anti-acne treatments with an excellent tolerance.     

痤疮患者血浆雄激素水平及白细胞雄激素受体的测定

为探讨痤疮患者外周血雄激素及白细胞雄激素受体（AR）含量对痤疮发生发展的影响，对35例痤疮患者和35名正常对照采用放射配体结合分析法测定白细胞雄激素受体含量，同时用放射免疫法检测血浆雄激素水平，结果：男性痤疮患者，血浆睾酮仅轻度升高，但其外周血白细胞AR的水平与对照组相比有明显升高（P＜0．05），女性痤疮患者，血浆睾酮水平及外周血白细胞AR水平与对照组相比均明显升高（P＜0．01），雄激素及其受体含量增高在女性痤疮的发病中可能起着重要的作用，痤疮的严重程度与睾酮水平及白细胞AR水平密切相关。     

A pilot study of the safety and efficacy of picolinic acid gel in the treatment of acne vulgaris

BACKGROUND: Cost limitations, adverse effects or lack of efficacy limit the use of current topical therapies in mild to moderate acne vulgaris. OBJECTIVES: To determine the safety and efficacy of picolinic acid, a novel zinc finger therapy, in the treatment of mild to moderate acne vulgaris. METHODS: Twenty subjects with mild to moderate acne vulgaris were treated at our centre during an open-label study with 10% picolinic acid gel (PCL-016) twice daily to the face over 12 weeks. RESULTS: Fifteen patients completed the 12-week open-label study. A reduction of 58.2% (P < 0.001) in mean total lesion count, 55.5% (P < 0.001) in mean inflammatory lesion count and 59.7% (P < 0.005) in noninflammatory lesion count was seen in this population. No serious adverse events or clinically significant changes in laboratory values were noted. CONCLUSIONS: Results from this study suggest that 10% picolinic acid gel applied twice daily may be safe and effective in the treatment of mild to moderate acne vulgaris.     

含乙醇酸、水杨酸、辛酰水杨酸和烟酰胺的外用配方改善轻、中度痤疮症状的临床观察

目的：评价含乙醇酸、水杨酸、辛酰水杨酸和烟酰胺的外用配方改善轻、中度痤疮临床症状的有效性和安全性。方法：招募66例轻、中度女性痤疮患者,按要求使用测试产品28 d后停用14 d,分别在使用前、使用7 d和28 d以及停用7 d和14 d后由皮肤科医生进行痤疮皮损计数、痤疮炎症后红斑和色素沉着计数、毛孔可见度和肤色均匀度评级,拍摄面部标准照片并进行图像分析,并由患者完成自我评价问卷。结果：共有42例患者完成全部试验。与使用前相比,测试产品在使用后7 d和28 d能显著减少非炎性和炎性皮损数量,改善毛孔可见度和肤色均匀度,并且在停用后14 d内仍能维持效果。此外,测试产品对于肤色、红斑程度/面积及血流灌注等图像分析指标也有显著的改善作用。患者对测试产品耐受良好,表现出了较高的满意度和持续使用的意愿。结论：含乙醇酸、水杨酸、辛酰水杨酸和烟酰胺的外用配方对于改善轻、中度痤疮临床症状具有较好的有效性和安全性,减少皮损同时能减轻痤疮炎症后红斑和色素沉着并改善肤质和肤色。     

异维A酸联合水杨酸治疗中重度痤疮的疗效观察

目的:探讨口服异维A酸胶囊联合30％超分子水杨酸治疗中重度痤疮的临床疗效.方法:将80例中重度痤疮患者随机分为对照组(40例)和观察组(40例),对照组给予异维A酸胶囊10 mg口服,一天2次,连续8周;观察组给予异维A酸胶囊的同时联合30％超分子水杨酸治疗,每隔4周治疗一次,共3次.比较两组患者总积分、临床疗效、不良...     

果酸联合丹参酮治疗痤疮疗效评价

目的:评价果酸联合丹参酮治疗寻常痤疮的疗效。方法:90例寻常痤疮患者随机分成两组,治疗组采用果酸治疗,每周2次,同时口服丹参酮胶囊,4粒/次,3次/d;对照组单纯用果酸治疗,8周后观察疗效。结果:治疗组有效率为80.43%,对照组为61.36%,两组疗效比较差异有显著性(P0.05),两组均未发现明显不良反应。结论:果酸联合丹参酮治疗寻常痤疮疗效较好。     

Improved efficacy and tolerability of retinoic acid in acne vulgaris: a new topical formulation with cyclodextrin complex ψ

OBJECTIVES: Retinoic acid (RA) has long been used, both topically and systemically, for disorders of keratinization, acne and related disorders. In the present study, the efficacy and tolerability of topical RA prepared as a cyclodextrin beta complex (beta-CD) is investigated in 66 acne vulgaris patients. METHODS: This randomized, double-blind, placebo-controlled study compares nightly topical application of RA/beta-CD complex hydrogel formulation (0.025%), RA/beta-CD complex in moisturizing base (0.025%), hydrogel base, moisturizer base or a commercial RA gel (0.05%) in acne vulgaris patients. Improvement of acne was assessed using a 5-point improvement scale and by measuring sebum and moisture content of the skin using an SM 810 sebumeter/corneometer. RESULTS: After 3 months of treatment, mean scores of acne improvement on the 5-point scale were 4 with the RA/beta-CD complex hydrogel formulation, 4.1 with the RA/beta-CD complex in moisturizing base, 1.2 with hydrogel placebo base, 1.1 with moisturizer placebo base and 3 with the commercial RA product. All patients treated with the commercial product experienced local side-effects. One patient discontinued due to severe irritation. None of the patients treated with the RA/beta-CD complex in the moisturizing base and hydrogel formulation experienced significant local irritation, although the sebum content of the skin decreased after application of the RA/beta-CD preparations. This change was not significant compared to controls. The moisture content of the skin was better preserved in the group treated with the RA/beta-CD complex in the moisturizing base. CONCLUSION: The topical RA/beta-CD complex, in hydrogel and moisturizing base, was more effective than the twice concentrated commercial RA product. There were few topical side-effects with this new formulation, which increases patient compliance. Topical RA/beta-CD (0.025% RA) did not significantly reduce sebum secretion but may help to preserve optimum epidermal moisture content with the proper base formulation. This is the first study in the literature reporting efficacy and tolerability of the topical RA/beta-CD complex in acne vulgaris. We conclude that the topical RA/beta-CD complex displays an improved efficacy and tolerability profile and is an effective treatment alternative for acne vulgaris.